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Abstract 
Background: Restrictive Allograft Syndrome (RAS) has been recently defined as a novel phenotype of 
chronic lung allograft dysfunction (CLAD) after lung transplantation. The goal was to describe CT 
changes of RAS patients and to correlate this with spirometry and survival. 
Methods: All 24 established RAS patients in our center were retrospectively included. CT scans in the 
pre-CLAD, CLAD, post-CLAD and late-CLAD stadium were systematically evaluated by a blinded 
observer using a semi-quantitative scoring system. Changes in CT patterns were correlated with 
spirometry and survival. 
Results: The most prominent CT features at diagnosis of CLAD compared to preCLAD were 
appearance of central (p=0.020) and peripheral ground glass opacities (p=0.052), as well as septal 
and non septal lines (p=0.020). Survival after diagnosis of CLAD was only associated with the absolute 
value of Forced Vital Capacity (FVC) at diagnosis (R=0.46 and p=0.021), but not with any CT 
alterations. Evolution of CT abnormalities after diagnosis of CLAD, included significant increases in 
(traction) bronchiectasis (p<0.0001), central (p=0.051) and peripheral (p=0.0002) consolidation, 
architectural deformation (p=0.0002), volume loss (p=0.0004) and hilus retraction (p=0.0036). The 
absolute FVC decrease post CLAD diagnosis correlated with CT alterations.    
Conclusion: In the early stages of RAS, central and peripheral ground glass opacities are the most 
prominent feature on CT, while in later stages bronchiectasis, traction, central and peripheral 
consolidation, architectural deformation, volume loss and hilus retraction are more pronounced. CT 
changes, however, could not predict survival, whereas the FVC at diagnosis of CLAD seems to be the 
best predictor of survival.  
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Introduction 
Lung transplantation is the ultimate treatment for patients with end-stage pulmonary disorders. 
Survival remains hampered by chronic rejection of which the clinical correlate is Bronchiolitis 
Obliterans Syndrome (BOS) with 50% of patients suffering from BOS 5 years after transplantation (1). 
For over 10 years BOS has been defined as a persistent, obstructive decline in forced expiratory 
volume in 1 second (FEV1) in the absence of confounding factors (2). However, nowadays the term 
chronic lung allograft dysfunction (CLAD) seems more appropriate as it became clear that there are 
different phenotypes of chronic rejection. First, it was observed that in 35% of so-called BOS patients, 
azithromycin could improve the FEV1 with ≥10%, an entity called neutrophilic reversible allograft 
dysfunction (3). In the broncho-alveolar lavage, these patients display high neutrophil (>15%) counts 
and on computed tomography (CT), these patients show more centrilobular abnormalities and signs 
of tree-in-bud, which resolves after treatment (4). Subsequently, attention has shifted to the 
azithromycin non-responsive CLAD patients. On the one hand, there is a strictly obstructive 
phenotype with air trapping on expiratory CT and small airway occlusions at pathological 
examination (obliterative/constrictive bronchiolitis). This pattern is seen in approximately 45% of all 
CLAD and 70% of all irreversible CLAD patients and is consistent with the definition of BOS. On the 
other hand a new phenotype has been defined based on a restrictive pulmonary physiology. The 
entity is defined by using a decline in total lung capacity (TLC) of at least 10% (5) or a progressive 
decrease in FEV1 and/or FVC with an increasing or stable FEV1/FVC ratio (6). This Restrictive Allograft 
Syndrome (RAS) accounts for approximately 30% of all patients suffering from irreversible CLAD and 
20% of all CLAD patients (5,6). Clinically, RAS patients have a median survival of 8 months (versus 35 
months for BOS patients) (6). The current study aimed to describe functional and radiological 
changes in patients, diagnosed with CLAD, who all fulfilled the RAS criteria.  
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Material and methods 
Patient characteristics 
Patients who underwent double lung or heart lung transplantation between 2001 and 2012 were 
retrospectively recruited. All patients provided written informed consent before transplantation. 
CLAD was defined as a persistent FEV1decline ≥20% compared to the mean of the 2 best post-
operative values. Subsequently, irreversible CLAD was defined as patients without an improvement 
in FEV1 after azithromycin therapy. Within the CLAD patient group, RAS was diagnosed in case of 
restrictive pulmonary function, based upon a decrease in TLC with at least 10%, when available or a 
FEV1/FVC ratio >0.70 (with declining FEV1 and FVC) when TLC is not available. For the purpose of the 
present study the CT at clinical diagnosis of CLAD was used as a reference scan (CLAD-CT). Pre-CLAD 
CT was the first CT preceding diagnosis of CLAD. Likewise the first post-CLAD CT (3 months to 1 year 
after diagnosis of CLAD) and the last available CT scans during follow-up were scored. We used the 
term CLAD as not all patients immediately develop the typical restrictive pulmonary function defect 
and we aimed to describe the radiological changes starting from the moment that the FEV1 
consistently remained under 20% of the best post-operative values. Pathology reports were available 
when patients underwent re-transplantation, open lung biopsy or autopsy and the typical findings 
were previously described by Ofek et al. and include extensive alveolar fibrosis, septal thickening but 
also obliterative bronchiolitis (7). 
CT protocol 
CT examinations were performed on a Siemens Somatom Sensation 16 or 64, a Siemens Definition 
Flash (Siemens AG, Erlangen Germany) or a Philips Brilliance 64 (Philips Medical Systems, Best, The 
Netherlands) without intravascular contrast media. One volumetric CT data set of the entire thorax 
was obtained in suspended deep inspiration in the supine position using 120kV and 140mAs and 
reconstructed as follows: 1/0.5mm axial, 5/5mm axial and 3/3mm coronal displayed in lung and 
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mediastinal window-centre settings. Another CT dataset was also obtained after breath-hold 
instruction at end- expiration with the patient supine but in a sequential mode with collimation 
2x1mm and table feed of 30mm using 120kV and 150mAs. Reconstructions of 1mm slice thickness 
were calculated and displayed in lung window-centre settings. 
 
CT scoring 
All the CT data sets were scored using semi-quantitatively scores based on previous descriptions 
(4,8). On inspiratory CT, the severity and extent of bronchus dilatation (and presence of traction) in 
the central and peripheral lung were scored, as was the extent of mucous plugging in large airways, 
extent of centrilobular nodules including tree-in-bud, extent and severity of airway wall thickening, 
extent of consolidation, extent of ground glass opacities, severity of architectural distortion, volume 
loss, displacement of the hilum, septal thickening and (sub)pleural thickening. The presence of an 
apicobasal gradient (apical dominant disease) was recorded. The extent of air trapping was scored on 
expiratory CT. In general, abnormalities were defined according to the Fleischner Society 
nomenclature (9). Bronchus dilatation was defined as a bronchus lumen diameter greater than the 
accompanying pulmonary artery outer diameter, lack of tapering of the bronchus or bronchi visible in 
the outer centimeter of the lung. Airway wall thickening was defined as a wall thickness to artery 
diameter ratio >0.2, this was assessed subjectively. Each abnormality was scored in five lung lobes, 
and per lobe the extent involved with the abnormality was estimated as less than one-third, between 
one-third and two-thirds, and more than two-thirds of the lobar volume or as mild, moderate or 
severe. To assess severity, this number was turned into percentages of the lung that are affected. 
Lung periphery was defined as the outer one-third of the lung. CT data sets were scored by one 
board certified chest radiologist (PDJ) with over 10 years of experience in reading chest CT scans for 
whom the reproducibility for most items has previously been described (8). CT examinations were 
scored blinded to the time-point of diagnosis. Both coronal and axial images were used for scoring. 
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Statistics 
All values displayed are mean±SEM. CT scorings before and at diagnosis of CLAD were compared 
using Wilcoxon matched pairs test. Evolution of CT throughout time (CT at diagnosis of CLAD, 3 to 12 
months after diagnosis and last available CT) were compared using a friedman test. Survival analysis 
was performed with Kaplan-Meier curve comparison. Correlation was performed using Spearman 
rank test. Spirometric values at the moment of the HRCT scan were used for this analysis. All 
statistics was performed using Graph pad prism 4.0 (GraphPad Software Inc., La Jolla, CA).  A p-value 
<0.05 was considered significant.   
 
Results 
Patient characteristics 
Detailed patient characteristics are provided in Table 1. 24 patients were ultimately diagnosed with 
RAS. At the end of the study period, 5 patients were alive and did not undergo re-transplantation, 10 
patients underwent re-transplantation and 9 patients died. Mean time of developing CLAD after 
transplantation was 1194±206 days. Mean time of follow-up after diagnosis of CLAD was 584±111 
days (182-3521 days). 50% graft loss after CLAD diagnosis was 501 days. At diagnosis of CLAD, 6 
patients fulfilled criteria for BOS but later on progressed to RAS, while 18 were immediately 
diagnosed with RAS. Most frequent complaints at diagnosis of CLAD were dyspnea (11/24, 45.8%), 
sputum (5/24, 20.8%) and cough (4/24, 16.7%). At the moment of the last CT, almost all patients 
suffered from dyspnea (23/24, 95.8%), while complaints of cough (10/24, 41.7%) and sputum 
production (8/24, 33.3%) were also frequently present.   
 
CT findings at the diagnosis of CLAD 
23 pre-CLAD CTs were available and compared with CLAD CT scans. The pre-CLAD CT was acquired 
210±22 days before diagnosis of CLAD. Twelve of 23 pre-CLAD CT scans did not show any 
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abnormalities based on all evaluated parameters. In the 11 remaining pre-CLAD CT scans, the most 
frequent finding was peripheral consolidation (11/23, 47.8% of patients) (Table 2). Survival of the 11 
patients with abnormalities on pre-CLAD CT was not significantly different compared to survival of 
the other 12 patients without abnormalities (p=0.49). Representative pre-CLAD CT scans from a 
patient with and without abnormalities and their progression is shown in figure 1 and 2 respectively. 
The CLAD-CT scans of 18/24 patients showed abnormalities. The severity of peripheral consolidation 
(p=0.064, 50.0% of patients), central ground glass (p=0.020, 33.3% of patients), peripheral ground 
glass (p=0.052, 50.0% of patients) and septal and non septal lines (p=0.020, 41.7% of patients) 
increased significantly from the pre-CLAD to CLAD CT. The number of patients showing an apicobasal 
gradient doubled from 3/24 patients to 6/24. There was no survival difference between patients with 
abnormalities at the moment of diagnosis of CLAD and those patients with a normal CT (p=0.16). As 
per definition, all spirometric data differed significantly at diagnosis of CLAD. FEV1, FVC and FEV1/FVC 
ratio significantly decreased (p<0.0001, p=0.002 and p=0.012) respectively. Survival after diagnosis of 
CLAD significantly correlated with absolute FVC (R=0.46 and p=0.021), FEV1/FVC ratio (R=-0.55 and 
p=0.0050) at diagnosis of CLAD and tended to correlate with the presence of central consolidation 
(R=0.38 and p=0.061). No other associations were seen between findings on CT at the time of CLAD 
diagnosis and survival. More details are displayed in table 2 and 3. 
 
Correlation between decline in pulmonary function and CT from pre CLAD to CLAD  
From pre-CLAD to CLAD, there was a significant correlation between the absolute FEV1-decrease and 
increase in bronchiectasis (R=-0.44 p=0.038) central ground glass (R=-0.43, p=0.047), peripheral 
ground glass (R=-0.43, p=0.047), architectural distortion (R=-0.42, p=0.049), volume loss (R=-0.42, 
p=0.049), and subpleural thickening (R=-0.63, p=0.0015). FVC decrease correlated significantly with 
bronchiectasis (R=-0.59; p=0.0038, peripheral consolidation (R=-0.48, p=0.025), central and 
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peripheral consolidation (R=-0.57, p=0.0052 and R=-0.61, p=0.0027) and pleural thickening (R=-0.54, 
p=0.0098). More details are shown in table 2 and 4. 
 
CT findings after the diagnosis of CLAD 
After CLAD was diagnosed, almost all parameters evolved over time. Between 3 to 6 months (mean 
163±20days) after diagnosis of CLAD, CT scans of 3 patients still failed to show any alterations 
(compared to CT of 6 patients at diagnosis) suggesting that these patients remained in BOS (also 
evidenced by the absence of restriction of sprirometry) and only later evolved to RAS. Remarkably, 
some patients showed improvement rather than deterioration on CT, although FEV1 further declined 
in all patients. A representative case is shown in figure 3. The last available CT scan (mean 443±87 
days after diagnosis) showed alterations in every patient compared to the CT at CLAD diagnosis. Most 
prominent CT features at that time were bronchiectasis (79.2% of patients), peripheral consolidation 
(95.8%), peripheral ground glass (66.7%), architectural distortion (75.0%) and volume loss (62.5%). 
Comparing CT scoring from CLAD-CT, post-CLAD CT and last CLAD CT, demonstrated a significant 
increase in bronchiectasis (from 11.4 to 38.9%, p=0.0001), peripheral consolidation (13.1 to 38.3%, 
p=0.012), central (from 13.0 to 20.0%, p=0.0057) and peripheral (from 20.8 to 31.9%, p=0.0082) 
ground glass, architectural deformation (4.2 to 20.3%, p=0.0002), volume loss (4.2 to 15.0%, 
p=0.0094) and hilus retraction (0.3 to 2.5%, p=0.0302). The number of patients with an apicobasal 
gradient increased from 6 to 9. Figure 4 illustrates a patient with evolution towards upper lobe 
fibrosis. FEV1 and FVC significantly decreased over time (p<0.0001 and p=0.0001 respectively). The 
FEV1/FVC ratio remained comparable from CLAD till last post CLAD CT scan. More details about the 
different scores are shown in table 3 and 4. 
 
Correlation between CT evolution and pulmonary function after diagnosis of CLAD  
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When correlating the changes in CT and the changes in pulmonary function from the moment of 
CLAD diagnosis until the last available post CLAD CT, significant correlations were found between the 
absolute FEV1 decline and central ground glass (R=0.57, P=0.0099), peripheral ground glass (R=0.67, 
p=0.0016), architectural distortion (R=-0.49, p=0.031) and a trend towards a significant correlation 
with bronchiectasis (R=-0.42, p=0.072) was seen. The absolute decline in FVC correlated significantly 
with bronchiectasis (R=-0.50, p=0.027), central ground glass (R=0.48, p=0.042), peripheral ground 
glass (R=0.48, p=0.039) and architectural distortion (R=-0.51, p=0.026) and a trend towards a 
significant correlation with hilus retraction (R=-0.43, p=0.069) was seen. Full details are shown in 
table 3. There were no correlations between alterations in CT and survival after CLAD diagnosis.  
 
Discussion 
In 24 patients who ultimately fulfilled the RAS criteria, we evaluated changes in CT patterns from the 
pre-CLAD to end-stage CLAD stadium in relation to pulmonary function and survival. The most 
prominent features at diagnosis of CLAD compared to the last pre-CLAD CT were appearance of 
central and peripheral ground glass and septal and non septal lines. Survival after diagnosis of CLAD 
was only associated with FVC at the moment of CLAD diagnosis, but not with any CT alterations. 
When comparing the evolution of CT findings after diagnosis of CLAD, there are significant increases 
in (traction) bronchiectasis, central and peripheral consolidation, architectural deformation, volume 
loss and hilus retraction. The FVC and FEV1 decrease correlated with CT alterations more specifically 
bronchiectasis, architectural deformation, central and peripheral ground glass.   
To our knowledge, only the Toronto group so far reported CT findings in RAS patients. They 
compared the last CT scan taken during follow-up of RAS patients (only the last CT-scan) to BOS and 
stable patients. End-stage RAS was characterized by significant changes in interstitial opacities, 
traction bronchiectasis, architectural distortion and ground glass opacities. These observations are 
very similar to the evolution that we observe in our RAS patients, although many more patients in 
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our study showed (traction) bronchiectasis. Central and peripheral ground glass, central and 
peripheral consolidation (with 95.8% of patients showing peripheral consolidation in their last CT 
scan), architectural distortion, volume loss, hilus retraction, septal and non-septal lines, airtrapping 
and subpleural thicking were prominent features of RAS CT scans. As shown in figure 4, some 
patients show total fibrosis of the upper lobes with a relative sparing of the lower lobes. In our 
experience, this is associated with end-stage RAS, in fact an increasing number of patients (9/24, 
37.5%) ultimately developed apical predominant fibrotic lesions, which is very comparable to the 
40% as described by Sato and upper lobe fibrosis after lung transplantation has been published 
previously by others as well (10). 
The added value of our study is that we compared the evolution within the same patients from pre-
CLAD to end-stage RAS. As such, we could see that in the early disease stage, 6/24 (25%) developed 
at first an obstructive spirometric defect without any CT abnormalities and were, hence, diagnosed 
with BOS. At initial diagnosis of CLAD, CT scans were characterized by an increase in central and 
peripheral ground glass, which correlate with the decrease in FVC. Later on, there is no significant 
increase in the % of central and peripheral ground glass, but rather an increase in bronchiectasis, 
architectural deformation, volume loss, peripheral consolidation and hilus retraction. However, of all 
these different CT patterns, only bronchiectasis and central and peripheral ground glass correlated 
significantly with the FVC evolution. 
As shown in figure 3 ground glass opacities seemed to resolve after an initial acute phase. This can be 
a response to treatment as the ground glass can be a manifestation of underlying infection or acute 
rejection. At the moment of CLAD this patient for example was treated with intravenous steroid 
pulse followed with oral tapered dose, but also with meropenem, tobramycine en ceftazidim which 
might explain the resolution of the ground glass. Nevertheless, the patient developed a restrictive 
pulmonary function defect, which persisted throughout time.  
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FVC at diagnosis of CLAD correlated with post-CLAD survival. This indicates that patients with an 
initial high FVC have a better survival after CLAD diagnosis; these are indeed the patients who were 
initially diagnosed with BOS and only later on evolved to RAS and as already described previously, 
BOS patients have a better survival compared to RAS patients (5,6). From our current results, it 
seems that the FVC decrease appears to be more predictive towards survival than specific changes 
on the CT. This is comparable to interstitial pulmonary fibrosis (IPF), where most studies use FVC 
evolution as an endpoint and not CT evolution (11). However, some patients are often too sick to 
perform pulmonary function tests, which makes it more difficult to link evolutionary changes in CT 
and spirometry, especially in the later stages of the disease (12). Sato et al. recently described a 
stepwise pattern of decline in pulmonary function towards RAS and noted ARDS-like early 
exacerbation with mainly ground glass on CT, which resolved but evolved in consolidation, reticular 
patterns and bronchiectasis (13). However they used mainly CT data during exacerbations and not at 
routine time points, whereas we report the CT evolution patterns, to be able to correlate CT changes 
with important clinical variables like spirometry and survival. We agree that some patients indeed 
start from an acute event (exacerbation), but 11 of our later RAS patients already showed presence 
of abnormalities on CT before the FEV1 decreased, which suggests that some early manifestations of 
RAS may be present which is not detected on pulmonary function and which is not characterized by 
an apparent exacerbation.  
In comparison with a previous study where radiological alterations in azithromycin responsive 
(neutrophilic CLAD) versus azithromycin non-responsive patients (mostly obstructive patients) were 
assessed, the biggest difference with the non-responders in that previous study and our current 
study is the small degree of air trapping in the RAS patients, which is in agreement with the 
previously reported results of the Toronto group (5). This indicates that air trapping is more specific 
for the BOS phenotype and occurs less frequently in the RAS patients. In patients who do have air 
trapping this may probably be a manifestation of the previous BOS diagnosis with underlying OB 
lesions being present. 
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This study has limitations as we have a high rate of re-transplantation within our RAS cohort, which 
might explain why we could not detect a correlation between CT changes and graft loss after 
diagnosis. Indeed, given the poor outcome of RAS, we have chosen to early retransplant these 
patients, at least when they qualify for it. Moreover the evolution of only 24 patients was described. 
This is, however, our entire RAS cohort. We started our study from the moment of CLAD diagnosis 
and not at the moment of RAS. This is because we lack sufficient TLC values to adequately judge the 
exact moment of diagnosing RAS. Therefore, we opted to start from the known fact that the FEV1 
decreased, which led to the initial diagnosis of CLAD. Doing so, we have an objective criteria for 
comparing findings in the pre-CLAD, CLAD- post-CLAD and late CLAD stadium. 
In conclusion, this study shows that in the early stages of RAS central and peripheral ground glass are 
the most prominent features on CT, while in the later stages bronchiectasis, traction, central and 
peripheral consolidation, architectural deformation, volume loss and hilus retraction are more 
observed. CT alteration are helpful to diagnose RAS but do not seem to be able to predict survival.  
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Table 1: Patient characteristics of the 24 patients who developed Chronic Lung Allograft Dysfunction 
and ultimately fulfilled the criteria of the RAS phenotype 
Age at transplant, years 36.8±3.5 
Underlying disease, n 
    Emphysema 9 
   Cystic fibrosis 5 
   Pulmonary fibrosis 4 
   Pulmonary hypertension 2 
   Other 4 
Male/Female, n 13/11 
Double lung/Heart-Lung 
transplantation, n 22/2 
Alive/Re-transplant/death 5//10//9 
Time of CLAD diagnosis, 
post transplant days 1194±206 
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Table 2: Prevalence of CT findings before, at and after the diagnosis of Chronic Lung Allograft 
Dysfunction 
  Pre-CLAD CLAD Post CLAD Last CLAD 
Bronchiectasis, n(%) 3 (13.0%) 7 (29.1%) 12 (52.2%) 19 (79.2%) 
Mucus, n(%) 3 (13.0%) 5 (20.8%) 2 (8.7%) 2 (8.3%) 
Nodules, n(%) 4 (17.4%) 6 (25.0%) 5 (21.7%) 3 (12.5%) 
Airway wall thickening, n(%) 1 (4.3%) 1 (4.2%) 2 (8.7%) 3 (12.5%) 
Consolidation central, n(%) 2 (8.7%) 4 (16.7%) 7 (30.4%) 12 (50%) 
Consolidation peripheral, n(%) 10 (43.5%) 12 (50.0%) 14 (60.9%) 23 (95.8%) 
Ground glass central, n(%) 1 (4.3%) 8 (33.3%) 10 (43.5%) 12 (50%) 
Ground glass peripheral, n(%) 5 (21.7%) 12 (50%) 14 (60.9%) 16 (66.7%) 
Architectural distortion, n(%) 3 (13.0%) 5 (20.8%) 11 (47.8%) 18 (75.0%) 
Volume loss, n(%) 3 (13.0%) 5 (20.8%) 9 (39.1%) 15 (62.5%) 
Hilus retraction, n(%) 1 (4.3%) 1 (4.2%) 3 (13.0%) 8 (33.3) 
Septal and non-septal lines, n(%) 3 (13.0%) 10 (41.7%) 9 (39.1%) 12 (50.0%) 
Thickening axial interstitium, n(%) 0 (0.0%) 2 (8.3%) 2 (8.7%) 3 (12.5%) 
(Sub)pleural thickening, n(%) 4 (17.3%) 8 (33.3%) 8 (34.8%) 9 (37.5%) 
Airtrapping, n(%) 4 (17.3%) 6 (25%) 5 (21.7%) 8 (33.3%) 
Apicobasal gradient, n(%) 3 (13.0%) 6 (25%) 7 (30.4%) 9 (37.5%) 
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Table 3:  Computed tomographic and spirometric evolution towards the diagnosis of CLAD 
 
                 CT fi ndings 
 
  Correlation with FEV1  Correlation with FVC  
  Pre- CLAD* CLAD P              R P  R P 
Bronchiectasis 7.2±4.5 11.4 ±4.5 0.22 -0.44 0.038  -0.59 0.0038 
Mucus 1.7±1.2 5.0 ±3.0 0.88 -0.37 0.086  -0.26 0.24 
Nodules  5.5±2.4 8.0±3.4 0.82 -0.20 0.37  -0.22 0.32 
Airway wall thickening 0.6±0.6 0.6 ±0.6 1.00 -0.31 0.16  -0.26 0.25 
Consolidation central 1.2±0.9 3.9 ±2.2 0.19 -0.07 0.74  -0.10 0.67 
Consolidation peripheral 7.5±2.9 16.1 ±4.4 0.064 -0.40 0.063  -0.48 0.025 
Ground glass central 0.9±0.9 13.0 ±4.5 0.020 -0.43 0.047  -0.57 0.0052 
Ground glass peripheral 5.8±3.1 20.8 ±6.1 0.052 -0.43 0.047  -0.61 0.0027 
Architectural deformation 2.6±1.6 4.2 ±2.2 0.32 -0.42 0.049  -0.39 0.07 
Volume loss 2.6±1.6 4.2 ±2.2 0.32 -0.42 0.049  -0.39 0.07 
Hilus retraction  0.3±0.3 0.3±0.3 1.00 0.08 0.70  -0.03 0.88 
Septal and non-septal lines 2.3±1.5 17.5±5.6 0.020 -0.19 0.39  -0.26 0.24 
Thickening axial interstitium 0.0±0.0 1.9±1.5 0.50 -0.10 0.66  -0.02 0.94 
Pleural thickening 2.3±1.0 5.6±2.0 0.22 -0.63 0.0015  -0.54 0.0098 
Airtrapping 2.9±1.6 6.9±3.3 0.63 -0.23 0.29  -0.18 0.41 
Apicobasal gradient  3 6 
 
   
  FEV1 (L) 2.75±0.17 1.96±0.14 <0.0001    
  FVC (L) 3.53±0.22 2.82±0.21 0.0005    
  FEV1/FVC ratio 79.34±2.3 72.04±3.08 0.012    
   
*Time before CLAD was 210±22 days. P-value represents the result of the Wilcoxon matched pair 
test.  Correlation analysis with the FVC and FEV1 decline was performed using a Spearman rank test 
using the scores of the pre-CLAD CT-last CT.  Significant p-values are presented in bold. CLAD=Chronic 
Lung Allograft Dysfunction. FEV1=Forced Expiratory Volume in the first second. FVC=Forced Vital 
Capacity.  
17 
 
Table 4:  Computed tomographic and spirometric evolution after the diagnosis of CLAD 
  
 
    CT finding 
  
    Correlation FEV1  Correlation FVC 
   CLAD Post CLAD Last CLAD p R p R p 
Bronchiectasis 11.4 ±4.5 22.0±5.8 38.9±6.5 0.0001 -0.42 0.072 -0.50 0.027 
Mucus 5.0 ±3.0 0.6±0.4 0.6±0.4 0.25 0.27 0.26 -0.05 0.84 
Nodules  8.0±3.4 5.2±2.4 3.1±1.9 0.080 0.31 0.19 0.06 0.75 
Airway wall thickening 0.6 ±0.6 0.9±0.6 1.7±0.9 0.27 0.043 0.86 0.25 0.29 
Consolidation central 3.9 ±2.2 8.1±2.9 11.1±3.3 0.080 -0.25 0.29 0.00 1.00 
Consolidation peripheral 16.1 ±4.4 20.0±5.2 38.3±5.1 0.012 -0.062 0.80 -0.17 0.48 
Ground glass central 13.0 ±4.5 19.7±6.1 20.0±6.0 0.0057 0.57 0.0099 0.48 0.042 
Ground glass peripheral 20.8 ±6.1 30.4±6.5 31.9±6.7 0.0082 0.67 0.0016 0.48 0.039 
Architectural deformation 4.2 ±2.2 12.4±3.7 20.3±4.4 0.0002 -0.49 0.031 -0.51 0.026 
Volume loss 4.2 ±2.2 9.3±3.0 15.0±3.7 0.0009 -0.10 0.67 -0.28 0.25 
Hilus retraction  0.3±0.3 0.9±0.5 2.5±0.8 0.0302 -0.15 0.53 -0.43 0.069 
Septal and non-septal lines 17.5±5.6 12.5±4.0 16.1±4.2 0.38 0.20 0.41 0.050 0.84 
Thickening axial interstitium 1.9±1.5 2.0±1.5 3.3±1.9 0.37 0.00 1.00 0.00 1.00 
Pleural thickening 5.6±2.0 7.5±2.5 10.3±3.3 0.062 0.21 0.39 0.0085 0.98 
Airtrapping 6.9±3.3 8.4±4.0 10.2±3.3 0.66 -0.27 0.27 0.0005 0.98 
Apicobasal gradient  6 7 9     
  FEV1 1.96±0.14 1.72±0.16 1.26±0.11 
 
  
  FVC 2.82±0.21 2.66±0.27 1.90±0.17 
 
  
  FEV1/FVC 72.04±3.08 68.0±4.0 69.6±3.9 
 
  
  
     
  
  The displayed p-value shows the results of the Friedman rank test. Correlation with the absolute 
FEV1 and FVC decline was performed with the Spearman rank test using the scores of the last CLAD 
CT-CLAD CT. Significant p-values are presented in bold. CLAD=Chronic Lung Allograft Dysfunction. 
FEV1=Forced Expiratory Volume in the first second. FVC=Forced Vital Capacity. 
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Figure legend 
Figure 1:  
A 55 year old, female patient with abnormalities on sagittal computed tomography (CT) 
reconstruction of the right lung before Chronic Lung Allograft Dysfunction (CLAD) diagnosis. CLAD 
was diagnosed 1316 days after double lung transplantation for sarcoidosis. The left panel shows the 
CT before development of CLAD with peripheral consolidation and peripheral ground glass being 
present. There is not much evolution visible on the next CT at CLAD diagnosis 43 days later. The last 
CT 441 days later shows a typical Restrictive Allograft Syndrome pattern with extensive peripheral 
ground glass, architectural distortion and traction bronchiectasis being present.  
 
Figure 2:  
A 28 year old, male patient without abnormalities on the computed tomography (CT) exam before 
Chronic Lung Allograft Dysfunction (CLAD) diagnosis. CLAD was diagnosed 2623 days after double 
lung transplantation for primary pulmonary hypertension. Last CT shows ground glass, consolidation, 
volume loss, architectural distortion, hilus retraction and traction bronchiectasis as signs of fibrosis in 
the upper lobe of the right lung.  
 
Figure 3:  
A 29 year old, female patient who at initial Chronic Lung Allograft Dysfunction (CLAD) diagnosis had a 
decrease in FEV1 and Total Lung Capacity (Restrictive Allograft Syndrome diagnosis), with 
concomitant peripheral and central ground glass and thickening of intra- and interlobular septa, 
which largely resolved on the last available computed tomography (CT) exam with some 
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development of traction bronchiectasis 155 days after RAS diagnosis. RAS was diagnosed 3521 days 
after initial transplantation for cystic fibrosis.    
 
Figure 4:  
A 23 year old female patient, transplanted for cystic fibrosis, with an initial slightly abnormal pre- 
Chronic Lung Allograft Dysfunction (CLAD) computed tomography (CT) examination with limited 
ground glass in the lower lobes. At the time of CLAD, ground glass and especially septal lines were 
extensively present. On the two CT exams after CLAD, progressive upper lobe architectural 
distortion, volume loss, consolidation and traction bronchiectasis developed with hilar retraction 
consistent with upper lobe fibrosis. This is the patient with the longest evolution of restrictive 
allograft syndrome (RAS) in our cohort. Time between diagnosis of CLAD and last CT (right lower 
panel) is 1909 days.  
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